Advertisement
UK markets close in 2 hours 26 minutes
  • FTSE 100

    8,069.40
    +29.02 (+0.36%)
     
  • FTSE 250

    19,665.88
    -53.49 (-0.27%)
     
  • AIM

    754.60
    -0.09 (-0.01%)
     
  • GBP/EUR

    1.1668
    +0.0024 (+0.20%)
     
  • GBP/USD

    1.2475
    +0.0013 (+0.10%)
     
  • Bitcoin GBP

    50,759.54
    -2,203.18 (-4.16%)
     
  • CMC Crypto 200

    1,354.87
    -27.70 (-2.00%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.85
    +0.04 (+0.05%)
     
  • GOLD FUTURES

    2,345.50
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,911.06
    -177.64 (-0.98%)
     
  • CAC 40

    7,986.07
    -105.79 (-1.31%)
     

Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial. This trial demonstrated that oral semaglutide significantly decreased the blood sugar levels in individuals with type 2 diabetes compared to placebo therapy.